Full Text Journal Articles by
Author Blase Polite

Advertisement

Find full text journal articles






Reply to S. Sorscher.

Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M Goldberg, Monica M Bertagnolli, Charles David Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P Venook, Heinz-Josef Lenz, Omar Kabbarah,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, :JCO1901366]

Cited: 0 times

View full text PDF listing >>



Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.

Blase N Polite, Abbe R Gluck, Otis W Brawley,

JAMA (JAMA)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

State of Cancer Care in America: Reflections on an Inaugural Year.

Blase N Polite, Jerome E Seid, Morganna Freeman, Laura A Levit, M Kelsey Kirkwood, Caroline Schenkel, Suanna S Bruinooge, Richard L Schilsky,

J Oncol Pract (Journal of oncology practice)
[2019, 15(4):163-165]

Cited: 0 times

View full text PDF listing >>



Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Federico Innocenti, Fang-Shu Ou, Xueping Qu, Tyler J Zemla, Donna Niedzwiecki, Rachel Tam, Shilpi Mahajan, Richard M Goldberg, Monica M Bertagnolli, Charles D Blanke, Hanna Sanoff, James Atkins, Blasé Polite, Alan P Venook, Heinz-Josef Lenz, Omar Kabbarah,

PURPOSE:CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(14):1217-1227]

Cited: 0 times

View full text PDF listing >>



Investigation of a multimedia, computer-based approach to improve knowledge, attitudes, self-efficacy, and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills.

Blase N Polite, Toni M Cipriano-Steffens, Chuanhong Liao, Edward L Miller, Nicole L Arndt, Elizabeth A Hahn,

BACKGROUND:Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. The authors tested an interactive technology designed for patients with diverse health literacy skills with the aim of improving patient receptiveness, willingness, knowledge, self-efficacy, and positive attitudes regarding clinical trials. METHODS:Patients presenting for ... Read more >>

Cancer (Cancer)
[2019, 125(12):2066-2075]

Cited: 0 times

View full text PDF listing >>



A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Manish R Sharma, Smita S Joshi, Theodore G Karrison, Kenisha Allen, Grace Suh, Robert Marsh, Mark F Kozloff, Blase N Polite, Daniel V T Catenacci, Hedy L Kindler,

BACKGROUND:FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) is an effective but toxic therapy for pancreatic cancer. UGT1A1 (UDP glucuronosyltransferase 1A1) eliminates the active metabolite of irinotecan. Polymorphisms reduce UGT1A1 activity, leading to toxicity. The primary objective was to determine the dose-limiting toxicity (DLT) rate in cycle 1 of modified FOLFIRINOX (mFOLFIRINOX) ... Read more >>

Cancer (Cancer)
[2019, 125(10):1629-1636]

Cited: 0 times

View full text PDF listing >>



Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Scott K Sherman, Joel J Lange, Fadi S Dahdaleh, Rahul Rajeev, T Clark Gamblin, Blase N Polite, Kiran K Turaga,

Importance:Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment's cost justifies its benefits has not been evaluated in the United States. Objective:This study sought to determine the influence ... Read more >>

JAMA Oncol (JAMA oncology)
[2018, :]

Cited: 0 times

View full text PDF listing >>



Engaging Patients in Value-Based Cancer Care: A Missed Opportunity.

S Yousuf Zafar, Blase N Polite, Mark McClellan,

JAMA Oncol (JAMA oncology)
[2018, 4(11):1479-1480]

Cited: 0 times

View full text PDF listing >>



Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial.

Fadi S Dahdaleh, Scott K Sherman, Elizabeth C Poli, Janani Vigneswaran, Blase N Polite, Manish R Sharma, Daniel V Catenacci, Steven B Maron, Kiran K Turaga,

BACKGROUND:Patients with colon cancer often present with obstruction. Large series have reported obstruction among the high-risk features, yet prospective data on its specific prognostic influence are lacking. We hypothesized that obstruction is an independent risk factor for poor prognosis in patients with stage III colon cancer. METHODS:N0147 was a trial ... Read more >>

Surgery (Surgery)
[2018, 164(6):1223-1229]

Cited: 0 times

View full text PDF listing >>



Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.

Michael R Marco, Lihong Zhou, Sujata Patil, Jorge E Marcet, Madhulika G Varma, Samuel Oommen, Peter A Cataldo, Steven R Hunt, Anjali Kumar, Daniel O Herzig, Alessandro Fichera, Blase N Polite, Neil H Hyman, Charles A Ternent, Michael J Stamos, Alessio Pigazzi, David Dietz, Yuliya Yakunina, Raphael Pelossof, Julio Garcia-Aguilar, ,

Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response.The purpose of this study was to analyze disease-free and overall survival.This was a nonrandomized phase II trial.The study ... Read more >>

Dis. Colon Rectum (Diseases of the colon and rectum)
[2018, 61(10):1146-1155]

Cited: 2 times

View full text PDF listing >>



The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

M Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Laura A Levit, Caroline Schenkel, Jerome E Seid, Blase N Polite, Richard L Schilsky,

PURPOSE:To describe the US hematology and medical oncology practice landscape and to report findings of the sixth annual ASCO Oncology Practice Census survey. PARTICIPANTS AND METHODS:ASCO used Medicare Physician Compare data to characterize oncology practices in the United States. Practice size, number of care sites, and geographic distribution were determined. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(7):e412-e420]

Cited: 5 times

View full text PDF listing >>



A New Look at the State of Cancer Care in America.

Blase N Polite, Jerome E Seid, Laura A Levit, M Kelsey Kirkwood, Caroline Schenkel, Suanna S Bruinooge, Stephen S Grubbs, Deborah Y Kamin, Richard L Schilsky,

J Oncol Pract (Journal of oncology practice)
[2018, 14(7):397-399]

Cited: 0 times

View full text PDF listing >>



A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Amikar Sehdev, Theodore Karrison, Yuanyuan Zha, Linda Janisch, Michelle Turcich, Ezra E W Cohen, Michael Maitland, Blase N Polite, Thomas F Gajewski, Ravi Salgia, Navin Pinto, Marc B Bissonnette, Gini F Fleming, Mark J Ratain, Manish R Sharma,

BACKGROUND:Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis. METHODS:Patients with advanced solid tumor were treated with sirolimus for 7 days followed by randomization to either sirolimus with metformin ... Read more >>

Cancer Chemother. Pharmacol. (Cancer chemotherapy and pharmacology)
[2018, 82(2):309-317]

Cited: 0 times

View full text PDF listing >>



Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Rebecca Wellmann, Brittany A Borden, Keith Danahey, Rita Nanda, Blase N Polite, Walter M Stadler, Mark J Ratain, Peter H O'Donnell,

BACKGROUND:Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities. METHODS:In total, 125 oncology drugs were analyzed for positive germline pharmacogenomic associations in journals with impact factors ... Read more >>

Cancer (Cancer)
[2018, 124(14):3052-3065]

Cited: 0 times

View full text PDF listing >>



Impact on Oncology Practices of Including Drug Costs in Bundled Payments.

Jeffery C Ward, Laura A Levit, Ray D Page, John E Hennessy, John V Cox, Deborah Y Kamin, Suanna S Bruinooge, Ya-Chen Tina Shih, Blase N Polite,

INTRODUCTION:This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. METHODS:An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non-small-cell lung cancer. First quarter 2016 Medicare reimbursement rates were used to calculate the average fee-for-service (FFS) reimbursement for these vignettes. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(5):e259-e268]

Cited: 2 times

View full text PDF listing >>



Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations.

Blase N Polite, Toni M Cipriano-Steffens, Fay J Hlubocky, Pascal Jean-Pierre, Ying Cheng, Katherine C Brewer, Garth H Rauscher, George A Fitchett,

This study explores whether externalizing religious and spiritual beliefs is associated with advanced-stage colon cancer at initial oncology presentation and whether this association is stronger for blacks than for whites.Patients who had newly diagnosed, invasive colon cancer were recruited at 9 sites in the Chicago metropolitan area. Eligible patients were ... Read more >>

Cancer (Cancer)
[2018, 124(12):2578-2587]

Cited: 0 times

View full text PDF listing >>



A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning.

Christine M Bestvina, Kristen E Wroblewski, Bobby Daly, Brittany Beach, Selina Chow, Andrew Hantel, Monica Malec, Michael T Huber, Blase N Polite,

Accurate understanding of the prognosis of an advanced cancer patient can lead to decreased aggressive care at the end of life and earlier hospice enrollment.Our goal was to determine the association between high-risk clinical events identified by a simple, rules-based algorithm and decreased overall survival, to target poor prognosis cancer ... Read more >>

J Palliat Med (Journal of palliative medicine)
[2018, 21(6):846-849]

Cited: 1 time

View full text PDF listing >>



An Update on Colorectal Cancer.

Lai Xue, Ashley Williamson, Sara Gaines, Ciro Andolfi, Terrah Paul-Olson, Anu Neerukonda, Emily Steinhagen, Radhika Smith, Lisa M Cannon, Blasé Polite, Konstantin Umanskiy, Neil Hyman,

Curr Probl Surg (Current problems in surgery)
[2018, 55(3):76-116]

Cited: 0 times

View full text PDF listing >>



Blase Polite on How Disparities Research Must Move Into an Era of Action.

Blase N Polite,

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2017, 31(10):709-10, 717]

Cited: 0 times

View full text PDF listing >>



The Road From Theory to Reality: Illuminating the Complexity of Prospective Cancer Bundles.

Blase N Polite,

J Oncol Pract (Journal of oncology practice)
[2018, 14(2):59-61]

Cited: 0 times

View full text PDF listing >>



Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes.

Abiola Ibraheem, Blase Polite,

Cancer (Cancer)
[2017, 123(24):4752-4756]

Cited: 0 times

View full text PDF listing >>



Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study.

Lindsey A Jones, Carol Estwing Ferrans, Blase N Polite, Katherine C Brewer, Ajay V Maker, Heather A Pauls, Garth H Rauscher,

PURPOSE:We explored a potential racial disparity in clinical delay among non-Hispanic (nH) Black and White colon cancer patients and examined factors that might account for the observed disparity. METHODS:Patients aged 30-79 years with a newly diagnosed colon cancer from 2010 to 2014 (n = 386) were recruited from a diverse sample of ... Read more >>

Ann Epidemiol (Annals of epidemiology)
[2017, 27(11):731-738.e1]

Cited: 0 times

View full text PDF listing >>



Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.

Robert de W Marsh, Mark S Talamonti, Marshall S Baker, Mitchell Posner, Kevin Roggin, Jeffrey Matthews, Daniel Catenacci, Mark Kozloff, Blase Polite, Michele Britto, Chi Wang, Hedy Kindler,

Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2 , irinotecan 180 mg/m2 , leucovorin 400 mg/m2 Day 1, 5-FU 2400 mg/m2  × 48 h IV, peg-filgrastim 6 mg SQ day 3, every 14 days) has substantial activity in metastatic PDAC. We wished to determine the tolerability/efficacy of peri-operative ... Read more >>

J Surg Oncol (Journal of surgical oncology)
[2018, 117(3):354-362]

Cited: 6 times

View full text PDF listing >>



Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Eirini Pectasides, Matthew D Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite, Manish R Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca J Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung-Hoon Min, Katie S Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T Agoston, David J Oh, Andrew Dunford, Aaron R Thorner, Matthew D Ducar, Bruce M Wollison, Haley A Coleman, Yuan Ji, Mitchell C Posner, Kevin Roggin, Kiran Turaga, Paul Chang, Kyle Hogarth, Uzma Siddiqui, Andres Gelrud, Gavin Ha, Samuel S Freeman, Justin Rhoades, Sarah Reed, Greg Gydush, Denisse Rotem, Jon Davison, Yu Imamura, Viktor Adalsteinsson, Jeeyun Lee, Adam J Bass, Daniel V Catenacci,

Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumors. To evaluate genomic heterogeneity, we sequenced paired ... Read more >>

Cancer Discov (Cancer discovery)
[2018, 8(1):37-48]

Cited: 18 times

View full text PDF listing >>



Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Blase N Polite, Lucile L Adams-Campbell, Otis W Brawley, Nina Bickell, John M Carethers, Christopher R Flowers, Margaret Foti, Scarlett Lin Gomez, Jennifer J Griggs, Christopher S Lathan, Christopher I Li, J Leonard Lichtenfeld, Worta McCaskill-Stevens, Electra D Paskett,

CA Cancer J Clin (CA: a cancer journal for clinicians)
[2017, 67(5):353-361]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
2.5319 s